Sequentia Biotech Raises €10 Million with EIC Fund and Seventure Partners

Sequentia Biotech raises new capital. The company specialising in omics data analysis using bioinformatics and deeptech has closed a series A financing round with ten million euros. The initiative was supported by the European Innovation Council (EIC Fund) and the venture capital manager Seventure Partners, with advice from Across Legal.

With these funds, Sequentia Biotech intends to introduce and expand its application for automated analysis of microbiome data and direct clinical information, marketed under the Mick brand. This is a product aimed at the biopharmaceutical and biomedical fields with which to base decision-making on data.

Walter Sanseverino, CEO and founder of the biotechnology company Sequentia Biotech together with Riccardo Aiese, told La Vanguardia that they had already managed to break even a few years ago thanks exclusively to public and recurring income.

Sequentia Biotech has accumulated clients in more than 65 countries

The biotech company boasts 800 projects for hospitals, research centres and multinational companies. Sequentia also offers solutions for the agriculture and biofuels sectors.

Sequentia Biotech was founded in 2013 under the umbrella of the Centre for Research in Agricultural Genomics (CRAG), where Walter Sanseverino was doing research. Its beginnings were scientific consultancy work in the field of plant genomics, but it soon entered the market for cloud software development.

After ten years of experience in the sector and bioinformatics projects executed in all omics fields for clients in more than 65 countries, Sequentia Bioetch is ranked among the top ten digital healthcare companies in Catalonia and among the top twenty in the RNA sector worldwide.

__

(Featured image by digitale.de via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us